KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) FCF Margin (2016 - 2025)

Historic FCF Margin for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to 23.74%.

  • Regeneron Pharmaceuticals' FCF Margin fell 43200.0% to 23.74% in Q4 2025 from the same period last year, while for Dec 2025 it was 28.45%, marking a year-over-year increase of 26500.0%. This contributed to the annual value of 28.45% for FY2025, which is 26500.0% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its FCF Margin stood at 23.74% for Q4 2025, which was down 43200.0% from 37.75% recorded in Q3 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' FCF Margin peaked at 3919.8% during Q1 2022, and registered a low of 4.89% during Q2 2024.
  • For the 5-year period, Regeneron Pharmaceuticals' FCF Margin averaged around 301.34%, with its median value being 27.98% (2023).
  • In the last 5 years, Regeneron Pharmaceuticals' FCF Margin surged by 38979200bps in 2022 and then plummeted by -38821900bps in 2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' FCF Margin (Quarter) stood at 44.78% in 2021, then soared by 3401bps to 1567.7% in 2022, then tumbled by -98bps to 24.41% in 2023, then rose by 15bps to 28.06% in 2024, then dropped by -15bps to 23.74% in 2025.
  • Its last three reported values are 23.74% in Q4 2025, 37.75% for Q3 2025, and 25.18% during Q2 2025.